Daewoong enters agreement with Medivir for markeing rights to cold sore treatment Xerclear

Published: 2010-08-25 06:56:00

Updated: 2010-08-25 06:56:00

Daewoong Pharm says it has signed an agreement with Swenden-based Medivir AB to distribute Medivir’s Xerclear (acyclovir and hydrocortisone) for non-prescription use (OTC) in Korea.

Xerclear is the first and only topical herpes labialis (cold sores) treatment clinically proven to help prevent ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK